Treatment of Mycosis Fungoides at Clinical Stage IIIA or IIIB with Erythroderma (T4)
Clinical Scenario
This protocol addresses Mycosis fungoides presenting at clinical stage IIIA or IIIB, defined by erythroderma (T4 skin involvement). European expert recommendations specifically guide systemic treatment decisions for patients in this advanced staging category.
Treatment Approach
At this stage, systemic therapy is indicated. Several options — spanning cytostatic agents and targeted approaches — are considered, with the most appropriate choice shaped by individual disease characteristics. The complete regimen, including specific agents, selection criteria, and clinical sequencing, is detailed in the full structured protocol.
References
DOI: 10.1016/j.ejca.2023.113343
- Recommendations for first-line treatment of MF stage IIIA and B.
- Gemcitabine is another cytostatic drug recommended for the treatment of advanced stage MF and SS.